System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Olivier Lairez is an expert in Cardiology at Centre Hospitalier Universitaire de Toulouse (France). As of October 2026, ScienceLeadR ranks Olivier Lairez in the top 1% of experts worldwide for Transthyretin Cardiac Amyloidosis, Transthyretin amyloidosis and Cardiomyopathies. Olivier Lairez has authored 449 publications, the most recent in 2026, and is an investigator in 35 clinical trials, 9 of them ongoing. SLR score: 1,639 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Olivier Lairez Centre Hospitalier Universitaire de Toulouse France
1 639 ScienceLeadR Reputation 1639

Unlock

Register Login
Network Map

Cardiology

Subspecialties: Biochemistry - Public Health - Internal Medicine

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2008 - 2026
Source: PubMed

Centre Hospitalier Universitaire de Toulouse

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 449

Citations

Citations: 11 582 1st author: 29 Last author: 56 Unique author: 7

Main journals

Arch Cardiovasc Dis 29
Archives of Cardiovascular Diseases Supplements 29
Eur Heart J 27
Archives of cardiovascular diseases. Supplements 23
MED NUCL 23

Best Journals

Eur Heart J 10
N Engl J Med 4
Circulation 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Rivaroxaban for Stroke Prevention in Hypertrophic Cardiomyopathy Without Atrial Fibrillation and With Impaired Left Atrial Reservoir Strain: Design and Rationale of the LA-HCM Randomized Trial.
PMID 42844166 — stroke, rivaroxaban, atrial fibrillation, cardiomyopathy, hypertrophic, cardiomyopathies		Eur Heart J Cardiovasc Imaging20260
Effect of Aficamten on Cardiac Structure and Function in Patients with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy.
PMID 42667274 — cardiomyopathy, hypertrophic, therapeutics, blood circulation, cardiomyopathies		Circulation Top journal20261
Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Results From ACACIA-HCM.
PMID 42663111 — exercise, heart failure, diastolic, cardiomyopathy, hypertrophic, cardiac myosins, therapeutics, blood circulation, cardiomyopathies		Circulation Top journal20261
Left Atrial Structure and Function, Clinical Outcomes, and Efficacy of Vutrisiran in Transthyretin Amyloidosis With Cardiomyopathy: A Secondary Analysis of the HELIOS-B Randomized Clinical Trial.
PMID 42616515 — muscular diseases, heart, cardiovascular diseases, prealbumin, atrial fibrillation, amyloidosis, therapeutics, amyloid, cardiomyopathies, transthyretin amyloidosis		JAMA Cardiol20260
Comparison of Local Investigator and Core Laboratory Assessment of Cardiac MRI-derived Left Ventricular Ejection Fraction in the MyocarditIRM Study.
PMID 42560173 — laboratories		Radiol Cardiothorac Imaging20260

Clinical Studies 35

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 4

By phase:

N/A 18
Phase 3 9
Phase 2 5
Phase 1 1
Phase 1/Phase 2 1
Phase 4 1

By status:

Completed 16
Active not recruiting 6
Unknown 6
Recruiting 4
Not yet recruiting 2
Terminated 1

By type:

Interventional 22
Observational 13

By Monocentric/Multicentric:

monocentric 15
multicentric2to4 2
multicentric5to9 3
multicentricup10 15

Main Topics

Cohort/Consortium Investigators 10

Ongoing Clinical Trials

9 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
CLEOPATTRA A research study to look at the effects of treatment with a medicine called coramitug (NNC6019 0001) in people with heart failure due to ATTR amyloidosis
2024-518899-31-00 — heart failure, heart, prealbumin, amyloidosis, research, therapeutics, amyloid, cardiomyopathies, transthyretin amyloid cardiomyopathy, transthyretin amyloidosis		Phase 3Recruiting2025
A study to determine if ALXN2220 is effective safe and tolerable in adults with Transthyretin Amyloid Cardiomyopathy (ATTR CM)
2023-506669-70-00 — safety, prealbumin, amyloid, cardiomyopathies, transthyretin amyloid cardiomyopathy, transthyretin amyloidosis		Phase 3Active not recruiting2024
TRITON CM A Study to Evaluate Nucresiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
2024-519917-72-00 — safety, prealbumin, amyloidosis, therapeutics, cardiomyopathies, transthyretin amyloidosis		Phase 3Not yet recruiting2025
A Phase 2 Multicenter Study to Test the Effects of ALXN2220 on Markers of Disease Severity and the Safety of Re Treatment in Patients with Transthyretin Amyloid Cardiomyopathy
2025-520506-35-00 — safety, prealbumin, therapeutics, amyloid, cardiomyopathies, transthyretin amyloid cardiomyopathy, transthyretin amyloidosis		Phase 2Active not recruiting2025
Care Pathway for Patients With Fabry s Disease (Fabry PATH)
NCT07485660 — signs and symptoms, diagnosis, fabry disease, men, women		N/ANot yet recruiting2026

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS